Novartis Pharmaceuticals - Polycythemia vera


Not provided

Rare Disease

Polycythemia vera


Novartis Pharmaceuticals

Access Program Information

The primary objective of this study is collect additional safety of INC424 (Ruxolitinib) in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who have either received prior treatment with commercially available agents or who have never received treatment.

The expanded access program (NCT01493414) is no longer available. Please call the manufacturer for further information or see new expanded access program for Polycythemia vera (NCT02292446).


Contact: (+41613241111)

  • Algeria
  • Argentina
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Colombia
  • Czech Republic
  • Egypt
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Israel
  • Italy
  • Kuwait
  • Mexico
  • Morocco
  • Netherlands
  • Poland
  • Portugal
  • Russian Federation
  • Saudi Arabia
  • South Africa
  • Spain
  • Thailand
  • Tunisia
  • United Arab Emirates
  • United Kingdom
  • Venezuela

Free Newsletter